Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis (NVS) Biosimilar of MabThera Approved in the EU

by Zacks Equity Research

Novartis AG (NVS) announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon.

    Celgene Presents Interim Results from Cancer Drug Study

    by Zacks Equity Research

    Celgene Corporation (CELG) announced encouraging results from an interim analysis of a phase IIIb study, MAGNIFY, on Revlimid.

      Does Roche Holding (RHHBY) Look to be a Great Value Pick?

      by Zacks Equity Research

      Roche Holding is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

        J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use

        by Zacks Equity Research

        Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.

          Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year

          by Zacks Equity Research

          Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.

            Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval

            by Zacks Equity Research

            Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.

              Why is Alnylam's (ALNY) Stock Close to 100% this Year?

              by Zacks Equity Research

              Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.

                Epizyme Provides Positive Interim Data on EZH2 Inhibitor

                by Zacks Equity Research

                Epizyme, Inc. (EPZM) announced positive interim data from an ongoing phase II study evaluating pipeline candidate tazemetostat as a monotherapy in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma

                  Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

                  by Zacks Equity Research

                  Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.

                    Why is Kite Pharma (KITE) Stock Up Close to 100% this Year?

                    by Zacks Equity Research

                    Shares of Kite Pharma, Inc. (KITE) were up around 5.6% on Thursday.

                      Allergan to Buy Keller Funnel, Boost Plastic Surgery Unit

                      by Zacks Equity Research

                      Allergan plc (AGN) announced a deal to acquire privately held medical device company Keller Medical, Inc, which makes Keller Funnel, for an undisclosed amount.

                        Roche Announces Data on Perjeta, Alecensa and Tecentriq

                        by Zacks Equity Research

                        Roche announced a series of data on various cancer drugs like Perjeta, Alecensa and Tecentriq at ASCO.

                          Arpita Dutt headshot

                          Key FDA Events to Watch Out for in Jun 2017

                          by Arpita Dutt

                          Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.

                            Novartis Reports Positive Data on Breast Cancer Drug Kisqali

                            by Zacks Equity Research

                            Novartis AG (NVS) announced positive data from the phase III study, MONALEESA-2 on breast cancer drug Kisqali.

                              Novo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B

                              by Zacks Equity Research

                              Novo Nordisk (NVO) announced that the FDA has approved the Biologics License Application (BLA) for Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B.

                                Novartis Biosimilar Pipeline, 2018 Growth Plans on Track

                                by Zacks Equity Research

                                Novartis AG (NVS) announced that the EMA has accepted its applications for biosimilar versions of AbbVie's (ABBV) Humira (adalimumab) and Johnson & Johnson's (JNJ) Remicade (infliximab) for review.

                                  Arpita Dutt headshot

                                  5 Drug Stocks in Focus on World MS Day

                                  by Arpita Dutt

                                  Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.

                                    Kite Pharma Cancer Drug BLA Gets Priority Review Status

                                    by Zacks Equity Research

                                    Kite Pharma, Inc. (KITE) announced that its biologics license application (BLA) for its experimental CAR-T therapy, axicabtagene ciloleucel has been accepted for priority review by the FDA.

                                      Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet

                                      by Zacks Equity Research

                                      Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.

                                        Puma Soaring After Neratinib FDA Panel Win, Time to Buy?

                                        by Zacks Equity Research

                                        Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast cancers.

                                          Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline

                                          by Zacks Equity Research

                                          We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.

                                            BioLineRx Makes Regulatory Submission for Trial of BL-8040

                                            by Zacks Equity Research

                                            BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).

                                              Roche's Arthritis Drug Gets FDA Nod for Label Expansion

                                              by Zacks Equity Research

                                              Roche Holdings AG (RHHBY) announced that the FDA has approved Actemra subcutaneous injection for the treatment of giant cell arteritis (GCA).

                                                Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

                                                by Zacks Equity Research

                                                Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.

                                                  Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain

                                                  by Zacks Equity Research

                                                  On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).